Literature DB >> 25639304

In vitro and in vivo anti-MRSA activities of nosokomycins.

Ryuji Uchida1, Hideaki Hanaki, Hidenori Matsui, Hiroshi Hamamoto, Kazuhisa Sekimizu, Masato Iwatsuki, Yong Pil Kim, Hiroshi Tomoda.   

Abstract

The anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of nosokomycins A to D discovered in the silkworm-MRSA infection screening was investigated. The minimum inhibitory concentration (MIC) values of nosokomycins for authentic MRSA and S. aureus strains were calculated to be 0.06 to 2.0 μg/mL. They also showed potent inhibitory activity against 54 clinically isolated MRSA strains. Furthermore, nosokomycin A proved effective in the mouse-MRSA infection model.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25639304     DOI: 10.5582/ddt.2014.01050

Source DB:  PubMed          Journal:  Drug Discov Ther        ISSN: 1881-7831


  6 in total

1.  Synergistic effects of vancomycin and β-lactams against vancomycin highly resistant Staphylococcus aureus.

Authors:  Fumiaki Tabuchi; Yasuhiko Matsumoto; Masaki Ishii; Keita Tatsuno; Mitsuhiro Okazaki; Tomoaki Sato; Kyoji Moriya; Kazuhisa Sekimizu
Journal:  J Antibiot (Tokyo)       Date:  2017-02-15       Impact factor: 2.649

2.  Paraphaeosphaeride D and berkleasmin F, new circumventors of arbekacin resistance in MRSA, produced by Paraphaeosphaeria sp. TR-022.

Authors:  Takuya Suga; Mayu Shiina; Yukihiro Asami; Masato Iwatsuki; Tsuyoshi Yamamoto; Kenichi Nonaka; Rokuro Masuma; Hidehito Matsui; Hideaki Hanaki; Susumu Iwamoto; Hideyuki Onodera; Kazuro Shiomi; Satoshi Ōmura
Journal:  J Antibiot (Tokyo)       Date:  2016-06-22       Impact factor: 2.649

3.  D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus.

Authors:  Fumiaki Tabuchi; Yasuhiko Matsumoto; Masaki Ishii; Keita Tatsuno; Mitsuhiro Okazaki; Tomoaki Sato; Kyoji Moriya; Kazuhisa Sekimizu
Journal:  J Antibiot (Tokyo)       Date:  2017-06-07       Impact factor: 2.649

Review 4.  Streptomyces as a Prominent Resource of Future Anti-MRSA Drugs.

Authors:  Hefa Mangzira Kemung; Loh Teng-Hern Tan; Tahir Mehmood Khan; Kok-Gan Chan; Priyia Pusparajah; Bey-Hing Goh; Learn-Han Lee
Journal:  Front Microbiol       Date:  2018-09-24       Impact factor: 5.640

5.  Anti-MRSA Activity of Actinomycin X2 and Collismycin A Produced by Streptomyces globisporus WA5-2-37 From the Intestinal Tract of American Cockroach (Periplaneta americana).

Authors:  Zhiyu Chen; Peiyu Ou; Lingyan Liu; Xiaobao Jin
Journal:  Front Microbiol       Date:  2020-04-07       Impact factor: 5.640

6.  A Bombyx mori Infection Model for Screening Antibiotics against Staphylococcus epidermidis.

Authors:  Aurora Montali; Francesca Berini; Alessio Saviane; Silvia Cappellozza; Flavia Marinelli; Gianluca Tettamanti
Journal:  Insects       Date:  2022-08-19       Impact factor: 3.139

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.